>> Could This Cheap NASDAQ Stock Be The #1 Play Of 2017? <<. Click to read more
Cannabis Science Inc (OTCMKTS:CBIS) reported that Purple Haze Properties Chief Executive Andrew Pitsicalis will be showcasing joint and individual medicinal products formulated with CBIS specially for “Jimi’s Cannabis Collection.” It will cover genetic strains and products that will be presented at the “Marijuana Business Conference and Expo.” The two companies are working together to introduce unique lines of superior cannabis products utilizing scientific genetics. They will develop an education platform to impart information about the progress related to cannabis research.
Unique concept of Lounges
Purple Haze Properties will be presenting its idea of the Purple Haze Lounges and will be looking at Los Angeles and Denver as the first opening locations and then Vancouver, B.C, and Jamaica, as prospective international future locations. The new ultra lounges will be spread on area of 20,000 sq. ft. and will have a concert hall, VIP memberships, restaurants, and charity foundation. The company intends to give the performer as well as patron an amazing cultural experience. The lounges will use the best video and music technologies.
Cannabis Science Inc (OTCMKTS:CBIS) informed that they decided to introduce the brand at the mega event which is the largest and oldest national cannabis trade event. Purple Haze is presenting Jimi’s Cannabis Collection of throat spray, strains, edibles, lotions and medical CBD topical creams. The medical product line will help in relieving symptoms, like pain management for throat problems, scars, burns and others. Cannabis Science will assist Purple Haze inform people by having kiosks in the locations to generate awareness among self-medicating patients, to educate on cannabis diagnosed conditions and ailments. The kiosk displays will offer educational access to customers in respect to historical prescriptions, relative strain and medication for ailments.
On Tuesday’s trading session, the stock price of CBIS declined more than 4% to close the trading session at $0.0305. The decline came at a share volume of 6.35 million compared to average share volume of 5.45 million.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of journaltranscript.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:
The Next Big Thing In Biotech?https://journaltranscript.com
Get our top rated alerts on the biotech sector
A new field of medicine needs attentionhttps://journaltranscript.com
Here are the reasons to invest in CMXC
Traders Need To Know This Nowhttps://journaltranscript.com
WallStreet is loading up on this stock. Find out why